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Abstract: Extensive evidence supports an important role for soluble oligomers of the 
amyloid -protein (A) in Alzheimer’s Disease pathogenesis. In the present study we 
combined intracerebroventricular (icv) injections with brain microdialysis technology in 
the fully conscious rat to assess the effects of icv administered SDS-stable low-n A 
oligomers (principally dimers and trimers) on excitatory and inhibitory amino acid 
transmission in the ipsilateral dorsal hippocampus. Microdialysis was employed to assess 
the effect of icv administration of A monomers and A oligomers on dialysate glutamate, 
aspartate and GABA levels in the dorsal hippocampus. Administration of A oligomers 
was associated with a +183% increase (p<0.0001 vs. A monomer-injected control) in 
dorsal hippocampal glutamate levels which was still increasing at the end of the 
experiment (260 min), whereas aspartate and GABA levels were unaffected throughout. 
These findings demonstrate that icv administration and microdialysis technology can be 
successfully combined in the awake rat and suggests that altered dorsal hippocampal 
glutamate transmission may be a useful target for pharmacological intervention in 
Alzheimer’s Disease. 
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1. Introduction 
 
Extensive evidence supports an important role for soluble oligomers of the amyloid -protein (A) 
in Alzheimer’s Disease (AD) pathogenesis [1]. To study the effects of soluble forms of A we have 
taken advantage of an amyloid precursor protein-over-expressing cell line (referred to as 7PA2) that 
secrete A peptides which migrate on SDS-PAGE at ~4, 8 and 12 kDa and are recognized by 
antibodies specific for the mid-region, N- and C-termini of A. These putative dimers and trimers 
potently block long-term potentiation (LTP) both in vivo and in vitro and perturb the memory of 
learned behavior, whereas A monomer has no adverse effects [2-4]. The dorsal hippocampus (DH) is 
a key brain region implicated in learning acquisition and memory consolidation [5] and contains 
excitatory glutamate and aspartate-containing afferent and efferent pathways and inhibitory GABA 
interneurons. Evidence from both postmortem and in vivo studies suggests that the hippocampus is 
significantly involved in the pathophysiology of AD [6, 7]. Here we combine intracerebroventricular 
(icv) injections with brain microdialysis via a surgically implanted microdialysis probe in the dorsal 
hippocampus of the fully conscious Wistar rat to compare the effect of icv administration of A 
oligomer with that observed for the A monomer on dialysate glutamate, aspartate and GABA levels 
in the ipsilateral dorsal hippocampus. 
 
2. Experimental Section 
 
The experimental protocols employed in the project were approved by the University College 
Dublin, Animal Research Ethics Committee and the Department of Health and Children (Ireland) in 
accordance with the European Community Directive, 86/609/EC, licence number B100/3367. All 
experiments were carried out using the male Wistar rat supplied by Harlem U.K. Animals were housed 
individually in a thermoregulated environment (22C) with a 12 hour light/dark cycle for the duration 
of the experiment. Food and water were available ad libitum. 
 
2.1. Aβ Monomer/Oligomer Preparation 
 
7PA2 conditioned medium (CM) was generated and fractionated as described previously [4]. 
Briefly, cells were allowed to condition glutamine- and serum-free Dulbecco’s Modified Eagle’s 
Medium and the resulting CM was concentrated 10-fold using a Centriprep Ultracel YM-3 filter. An 
aliquot of concentrate (1 mL) was chromatographed on a Superdex 75 10/300 GL column and eluted 
with 50 mM ammonium acetate pH 8.5 in 1 mL fractions. Aliquots of each fraction (300 µL) were 
used for Western blotting to identify monomer and oligomer-containing fractions (Figure 2A) and the 
remaining 700 µL of monomer and oligomer-enriched fractions were stored at -80°C pending use. 
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2.2. Microdialysis 
 
Microdialysis enables the sampling of chemicals from the extracellular space of brain tissue via the 
microdialysis probe. The probe consists of a semi-permeable polycarbonate membrane (20,000 Dalton 
cut-off) mounted between the tip of an inner steel inlet cannula and an outer steel outlet shaft  
(Figure 1). Ringer perfusate is pumped at a controlled flow-rate into the membrane space of the probe 
through two holes in the inner cannula. Here, chemicals in the surrounding extracellular space 
passively diffuse across the membrane into the perfusate which then exits the probe for collection via 
the outer shaft. Thus, a representative proportion of the extracellular chemicals are measured by 
microdialysis as opposed to the absolute concentration of chemicals in the extracellular space. 
 
Figure 1. Schematic representation of the microdialysis probe employed in the present 
study showing the inlet cannula where perfusate enters the probe, the outlet where dialysate 
exits the probe and the semi-permeable dialysis membrane (1mm length and 500m outer 
diameter) at the tip of the probe positioned in the extracellular space of the dorsal 
hippocampus. 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Intra-Ventricular Cannulation and Intra-Hippocampal Microdialysis Probe Implantation  
 
Each rat was anaesthetised under isoflurane (4-2% in air) inhalation using a Univentor 400 
anaesthesia unit (Univentor, Malta) (delivered at 3.4 mL/min, air flow 500 mL/min) via a modified 
mouthpiece to maintain anaesthesia during surgery. The rat was then placed in a Kopf stereotaxic 
frame (David Kopf Instruments, USA) and stabilised with blunt ear bars to prevent damage to the 
tympanic membrane. A 1 mg/kg dose of rimadyl (Pfizer, U.K.) was administered (s.c.) as an analgesic. 
The incisor bar was set at -3.3 mm. During surgery the body temperature was continuously maintained 
at 37C with a thermostatically regulated heating pad (CMA 150, Carnegie Medicin AB, Sweden). The 
parietal and the frontal bones were exposed by a sagittal incision of the scalp at the midline from the 
level of the eyes to the occipital protuberance. Two holes (0.8 mm outer diameter) were drilled 
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according to stereotaxic co-ordinates [8] through the left side of the skull bone and the dura were 
carefully punctured. A 4 mm intraventricular (icv) injection cannula and a 1 mm concentric 
microdialysis probe (Carnegie Medicine AB, Stockholm, Sweden) were surgically implanted to the left 
lateral ventricle (AP -0.8 mm, ML +1.3 mm) and ipsilateral DH (AP -3.8 mm, ML -1.5 mm, DV -3.4 
mm) respectively according to stereotaxic co-ordinates. A fresh injection cannula and microdialysis 
probe was used for each rat. Sterile Ringer solution (Baxter, U.K., composition in mmol/l 
concentrations: Na+ 147; K+ 4; Ca2+ 2.2; Cl_ 156, pH 6) was perfused at a constant flow rate of 2 
L/min through the microdialysis probe using a microperfusion pump (CMA 100; Carnegie Medicin 
AB, Sweden) during probe implantation. Rats were given 48 hours to recover from surgery and 
received a high calorie (5% sucrose) solution to prevent dehydration and loss of body weight for the 
first 24 hours. 
On completion of the experiment rats were sacrificed by pentobarbital (Euthatal, Rhone Merieux, 
Harlow, UK) overdose after which the brain was removed and immersion-fixed in 4% 
paraformaldheyde in preparation for visual verification of cannula and probe positioning. Animals with 
incorrect positioning were not included in the study. 
 
2.4. Experimental Procedure 
 
Each rat was placed in a hemispherical experimental microdialysis bowl (40cm diameter) (BAS, 
U.S.A.). The previously implanted microdialysis probe was connected to a microperfusion pump and 
ringer solution perfused at 2 µL/min. Following a 300 min washout period [9], three successive basal 
dialysate fractions (60 min) were collected and immediately following this a 20 µL aliquot of either 
monomer or oligomer was injected icv (Figure 2). The A monomer-injected group acted as control. A 
further 13 successive fractions (260 min) were collected for GABA, glutamate and aspartate analysis. 
 
Figure 2. Schematic representation of the time course of microdialysis perfusion in the 
dorsal hippocampus and ipsilateral intracerebroventricular (icv) injection. Dialysate 
samples were not collected during equilibration (300 min) but were collected every 20 min 
thereafter yielding three baseline samples (-60 min) and 13 treatment samples collected 
260 min following icv injection.  
 
 
 
 
 
2.5. Neurotransmitter Analysis 
 
Dialysate glutamate and aspartate levels were quantified using pre-column ortho-phthalaldehyde 
(OPA) derivatization in the microsampler followed by separation via isocratic High Performance 
Liquid Chromatography (HPLC) coupled to fluorimetric detection [10]. A 10 L aliquot from each 
(-300 min) -60 min
Disconnection
Equilibration Baseline
0 min
(Aß)Connection
260 min
Treatment
Sensors 2008, 8  
 
 
7432
dialysate sample was pipetted into 0.3 mL eppendorfs and placed in a CMA 200 refrigerated 
microsampler (Carnegie Medicine AB, Sweden). Distilled H2O and a 2.5 M glutamate/aspartate 
standard solution were analysed regularly to check for contamination and reliability. As part of the 
precolumn derivatization process the microsampler was programmed to add 5.4 L of a derivatization 
reagent containing (OPA) and 2-mercaptoethanol to the dialysate sample prior to injection onto the 
HPLC column. The reaction was allowed to proceed for 120 seconds and then 14 L of the derivatized 
sample was injected onto the column. The total run time sample separation and detection was typically 
12 min. Retention time for glutamate and aspartate was typically 3.3 minutes and 1.8 minutes 
respectively with the limit of detection being 30 fmol/sample (Figure 3). 
 
Figure 3. Sample high performance liquid chromatograms of glutamate and aspartate (left) 
and GABA (right) from 20 min dialysate samples collected from the dorsal hippocampus 
of the awake rat (A) 20 min prior to (basal) and (B) 200min following an ipsilateral icv 
injection of the A oligomer. 
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Dialysate GABA levels were detected following a pre-column OPA derivatization followed by 
reverse phase HPLC coupled to electrochemical detection [11]. A 10 l aliquot from each dialysate 
sample was pipetted into 0.3 mL eppendorfs and placed in a CMA 200 refrigerated microsampler. 
Distilled H2O and a 25 nM GABA standard solution were analysed regularly to check for 
contamination and reliability. As part of the precolumn derivatization procedure the microsampler was 
programmed to add 0.5 L of a derivatization reagent containing OPA and 2-methyl-2-propanethiol to 
the dialysate sample prior to injection onto the HPLC column. The reaction was allowed to proceed for 
120 seconds and then 9 L of the derivatized sample was injected onto the column. The total run time 
for sample separation and detection was typically 12-14 min. Retention time for GABA was 3.8 
minutes and limit of detection was 50 fmol/sample (Figure 3). 
 
2.6. Data Presentation and Statistical Analysis 
 
Data are reported either as raw data or as normalised percentage change from basal levels 
(calculated as the mean of the two dialysate samples prior to icv injection) in the form of mean  
standard error of the mean (SEM). Statistical analysis between groups was performed using a two-way 
analysis of variance (ANOVA) with Bonferroni post-hoc analysis. P values are quoted where 
appropriate with P<0.05 considered significant. 
 
3. Results and Discussion  
 
3.1. Basal Dialysate Amino Acid Levels  
 
Basal dialysate glutamate, GABA and aspartate levels (raw data) did not differ between the two 
experimental groups prior to ipsilateral icv A monomer or oligomer injection (Table 1). 
 
Table 1. Basal dialysate glutamate, aspartate and GABA levels (absolute levels) in dorsal 
hippocampus measured prior to ipsilateral icv injection of either the A monomer or 
oligomer. Each value represents the mean ± standard error of the mean (SEM) of three 
consecutive 20 min dialysate fractions (60min) collected prior to ipsilateral icv Aβ 
injection (n= 5-7 animals per group). 
 Glutamate (µM) Aspartate (µM) GABA (nM) 
A-monomer 1.07 ± 0.19 0.07 ± 0.01 6.22 ± 1.10 
A-oligomer 1.25 ± 0.52 0.05 ± 0.01 9.09 ± 2.41 
 
3.2. Effect of Aβ Monomer and Oligomer 
 
An icv injection of the A monomer had no effect on ipsilateral dorsal hippocampal dialysate 
glutamate, aspartate or GABA levels. In contrast, icv injection of the A oligomer was associated with 
a gradual and prolonged selective +55% increase (vs. basal pre-treatment levels) in dialysate glutamate 
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levels representing a +92% increase when normalised against the A monomer-injected group 
(p<0.0001 vs. A monomer-injected control) and was still increasing at the end of the experiment 260 
min post-icv injection. Aspartate and GABA levels were not affected (Figure 4). 
 
Figure 4. (A) Western blot analysis of size exclusion chromatography (SEC) fractionated 
7PA2 conditioned medium (CM) with fractions (7 and 9) used for icv injection indicated 
by red boxes. The positions of A monomer (M) (~4 kDa), dimer (D) and trimer (T) bands 
(~8, ~12-14 kDa) are indicated with arrows. (B) Transverse sections of rat brain showing 
injection cannula track to the left lateral ventricle and microdialysis probe track in the 
ipsilateral dorsal hippocampus. Scale bar ≈ 2mm. (C) Dialysate glutamate, aspartate and 
GABA levels in the dorsal hippocampus following an intraventricular (icv) A monomer 
and oligomer injection. Data are presented as histograms (mean ± SEM) representing 
percent change (260 min) from A monomer-injected control group in the dorsal 
hippocampus following ipsilateral icv injection. See Table 2 and text for values. N=5-7 
animals per group. ***=P<0.0001 vs. monomer-injected control (ANOVA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dialysate levels of the excitatory amino acid neurotransmitters glutamate, aspartate and the 
inhibitory amino acid neurotransmitter GABA are at least in part derived from neuronal pools. Thus, 
dialysate glutamate and aspartate levels in the hippocampus are derived from local afferent and 
efferent pathways while GABA is derived from local interneurons. Falkenberg et al. [12] reported that 
injections of the glutamate receptor agonist quisqualate into the lateral entorhinal cortex increased 
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dialysate GABA levels in the hippocampus CA1 region and that this GABA increase was attenuated 
by local administration of the sodium channel antagonist tetrodotoxin, indicating a neuronal origin. 
Furthermore, perfusion with the glutamate receptor agonist N-methyl-D-aspartic acid (NMDA) into the 
lateral entorhinal cortex increases dialysate glutamate release in the ipsilateral dorsal  
hippocampus [13]. In the present study the gradual and prolonged A oligomer-induced increase in 
dialysate glutamate levels in the dorsal hippocampus suggests an increase in local afferent/efferent 
glutamate-mediated excitatory transmission, inhibition of reuptake and/or neurotoxicity while the lack 
of effect on aspartate indicates that glutamate and aspartate may originate from separate neuronal pools 
in this brain region. Previous studies report a differential release of aspartate and glutamate in the 
striatum, prefrontal cortex and hippocampus [14, 15]. The lack of an effect of A oligomers on local 
GABA release demonstrates a neuronal specificity for local excitatory glutamatergic transmission 
within the dorsal hippocampus and suggests a neuronal specificity whereby release and/or reuptake 
from local glutamate-containing afferent and efferent pathways, but not local GABA interneurons, 
within the dorsal hippocampus are targets for A oligomer action. 
 
Table 2. Dorsal hippocampal dialysate glutamate, aspartate and GABA levels following 
ipsilateral icv injection of either the Aβ monomer or oligomer expressed as percent change 
from basal (calculated as the mean of the two 20 min dialysate samples prior to icv Aβ 
injection). Each value represents the mean ± standard error of the mean (SEM) of thirteen 
20 min dialysate fractions (260 min) collected following Aβ injection. See Table 1 for 
absolute basal levels. (n= 5-7 animals per group). ***=P<0.0001 vs. monomer-injected 
control (ANOVA). 
 Glutamate  Aspartate GABA  
Aβ-monomer - 19 ± 28 - 10 ± 20 + 11 ± 11 
Aβ-oligomer + 55 ± 45 *** + 6 ± 20 - 6 ± 11 
 
4. Conclusions 
 
The present findings demonstrate that icv injection and microdialysis technologies can be 
successfully combined in the awake rat to demonstrate a selective and prolonged A oligomer-induced 
increase in local glutamate levels in the ipsilateral dorsal hippocampus. The appropriate balance 
between the excitatory (glutamate) and inhibitory (GABA) neurotransmitter systems in this brain 
region is essential for normal neuronal function, while an imbalance may be neurotoxic [16]. Thus, the 
ability of low to sub-nanomolar concentrations of A oligomers to induce this selective increase in 
excitatory glutamatergic transmission within the dorsal hippocampus suggests a highly sensitive 
neurochemical substrate for Alzheimer’s Disease. Similarly, the lack of effect of similar concentrations 
of A monomer is in keeping with our prior observations that monomer does not alter LTP or learned 
behavior, whereas oligomers potently inhibit LTP and perturb the memory of learned behavior. Taken 
together these findings could provide a useful avenue for pharmacological intervention in the treatment 
of Alzheimer’s Disease. 
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